阿托伐他汀和普伐他汀对接受抗逆转录病毒治疗的HIV-1感染患者免疫激活及T细胞功能的影响。
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
作者信息
Overton Edgar Turner, Sterrett Sarah, Westfall Andrew O, Kahan Shannon M, Burkholder Greer, Zajac Allan J, Goepfert Paul A, Bansal Anju
机构信息
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294 USA.
Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL, 35294 USA.
出版信息
AIDS. 2014 Nov 13;28(17):2627-2631. doi: 10.1097/QAD.0000000000000475.
Abstract
This retrospective study was designed to assess statin effects on T-cell activation from HIV-infected individuals. Peripheral blood mononuclear cells from antiretroviral therapy suppressed HIV-infected individuals receiving atorvastatin or pravastatin were evaluated for T-cell activation, exhaustion and function. Atorvastatin was associated with a significant reduction in CD8 T-cell activation (HLA-DR, CD38/HLA-DR) and exhaustion (TIM-3, TIM-3/PD-1) whereas pravastatin had no effect. In contrast, pravastatin increased antigen specific interferon γ production. These results suggest a differential effect of statins on immune activation and function.
摘要
这项回顾性研究旨在评估他汀类药物对HIV感染者T细胞激活的影响。对接受抗逆转录病毒治疗的HIV感染者服用阿托伐他汀或普伐他汀后外周血单个核细胞的T细胞激活、耗竭及功能进行了评估。阿托伐他汀与CD8 T细胞激活（HLA-DR、CD38/HLA-DR）及耗竭（TIM-3、TIM-3/PD-1）的显著降低相关，而普伐他汀则无此作用。相反，普伐他汀增加了抗原特异性干扰素γ的产生。这些结果表明他汀类药物对免疫激活和功能有不同的作用。
相似文献
1
Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.
AIDS. 2014 Nov 13;28(17):2627-2631. doi: 10.1097/QAD.0000000000000475.
2
Atorvastatin reduces T-cell activation and exhaustion among HIV-infected cART-treated suboptimal immune responders in Uganda: a randomised crossover placebo-controlled trial.
Trop Med Int Health. 2015 Mar;20(3):380-90. doi: 10.1111/tmi.12442. Epub 2015 Jan 6.
3
Rosuvastatin, pravastatin, and atorvastatin for the treatment of hypercholesterolaemia in HIV-infected patients receiving protease inhibitors.
Curr HIV Res. 2008 Nov;6(6):572-8. doi: 10.2174/157016208786501481.
4
The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin.
J Clin Lipidol. 2012 Jan-Feb;6(1):42-9. doi: 10.1016/j.jacl.2011.08.006. Epub 2011 Sep 13.
5
Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
J Am Coll Cardiol. 2008 Sep 9;52(11):914-20. doi: 10.1016/j.jacc.2008.05.046.
6
Vitamin D supplementation decreases immune activation and exhaustion in HIV-1-infected youth.
Antivir Ther. 2018;23(4):315-324. doi: 10.3851/IMP3199.
7
Effect of statins on LDL particle size in patients with familial combined hyperlipidemia: a comparison between atorvastatin and pravastatin.
Nutr Metab Cardiovasc Dis. 2005 Feb;15(1):47-55. doi: 10.1016/j.numecd.2004.08.001.
8
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
Curr Med Res Opin. 2001;17(4):267-72.
9
Believe-it then PROVE-IT.
Int J Clin Pract. 2004 Apr;58(4):325-6. doi: 10.1111/j.1368-5031.2004.00220.x.
10
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Am J Cardiol. 2002 Apr 1;89(7):860-1. doi: 10.1016/s0002-9149(02)02201-4.
引用本文的文献
1
A Dual Pharmacological Strategy against COVID-19: The Therapeutic Potential of Metformin and Atorvastatin.
Microorganisms. 2024 Feb 13;12(2):383. doi: 10.3390/microorganisms12020383.
2
Cholesterol induction in CD8 T cell exhaustion in colorectal cancer via the regulation of endoplasmic reticulum-mitochondria contact sites.
Cancer Immunol Immunother. 2023 Dec;72(12):4441-4456. doi: 10.1007/s00262-023-03555-8. Epub 2023 Nov 3.
3
A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy.
Int J Environ Res Public Health. 2023 Apr 27;20(9):5668. doi: 10.3390/ijerph20095668.
4
Impaired response of memory Treg to high density lipoproteins is associated with intermediate/high cardiovascular disease risk in persons with HIV.
Front Immunol. 2023 Mar 10;14:1146624. doi: 10.3389/fimmu.2023.1146624. eCollection 2023.
5
Defying convention in the time of COVID-19: Insights into the role of γδ T cells.
Front Immunol. 2022 Aug 11;13:819574. doi: 10.3389/fimmu.2022.819574. eCollection 2022.
6
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions.
Curr Opin HIV AIDS. 2022 Sep 1;17(5):293-300. doi: 10.1097/COH.0000000000000752. Epub 2022 Jul 16.
7
The Binary Model of Chronic Diseases Applied to COVID-19.
Front Immunol. 2021 Sep 3;12:716084. doi: 10.3389/fimmu.2021.716084. eCollection 2021.
8
Are statins beneficial for the treatment of SARS-CoV-2 infection?
J Infect Prev. 2021 Jul;22(4):177-180. doi: 10.1177/1757177420982049. Epub 2021 Jan 12.
9
RORα Regulates Cholesterol Metabolism of CD8 T Cells for Anticancer Immunity.
Cancers (Basel). 2020 Jun 29;12(7):1733. doi: 10.3390/cancers12071733.
10
Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef-AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells.
Front Immunol. 2019 Sep 10;10:2151. doi: 10.3389/fimmu.2019.02151. eCollection 2019.
本文引用的文献
1
Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.
J Immunol. 2013 Sep 1;191(5):2194-204. doi: 10.4049/jimmunol.1200646. Epub 2013 Aug 5.
2
Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.
Clin Infect Dis. 2013 May;56(10):1471-9. doi: 10.1093/cid/cit053. Epub 2013 Feb 5.
3
Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells.
J Immunol. 2012 Oct 15;189(8):3838-47. doi: 10.4049/jimmunol.1201488. Epub 2012 Sep 10.
4
Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection.
PLoS One. 2012;7(7):e40146. doi: 10.1371/journal.pone.0040146. Epub 2012 Jul 5.
5
Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease.
PLoS One. 2012;7(3):e24243. doi: 10.1371/journal.pone.0024243. Epub 2012 Mar 20.
6
HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.
AIDS. 2012 Apr 24;26(7):843-53. doi: 10.1097/QAD.0b013e328351f756.
7
Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.
J Infect Dis. 2011 Oct 15;204(8):1227-36. doi: 10.1093/infdis/jir520.
8
Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.
J Infect Dis. 2011 Oct 15;204(8):1217-26. doi: 10.1093/infdis/jir507.
9
Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.
AIDS Res Hum Retroviruses. 2012 May;28(5):469-77. doi: 10.1089/aid.2011.0213. Epub 2011 Sep 27.
10
Association between use of HMG CoA reductase inhibitors and mortality in HIV-infected patients.
PLoS One. 2011;6(7):e21843. doi: 10.1371/journal.pone.0021843. Epub 2011 Jul 12.
Zotero 插件